We sincerely thank ESGtimes – Sustainable Times for the interview and in-depth feature, which allows more people to better understand PrecisemAb’s journey in antibody engineering and precision medicine, as well as the core thinking that has guided us along the way.
In the interview, our Chief Scientific Officer, Dr. Yi An Cheng, shared a key principle that has shaped our long-term focus:
“We are not simply pursuing stronger antibodies. We are asking whether antibodies can be activated only where they are needed, so that we can fundamentally reduce the risk of side effects.”
This mindset reflects a central question we have continuously examined as we transitioned from academic research to industrial development: how to identify solutions that are not only efficacious but also clinically and commercially acceptable in balancing efficacy and safety.
If you would like to learn more about PrecisemAb’s background, the scientific rationale behind our platform, and how we are building a globally competitive antibody technology, we invite you to read the full interview at the link (here).
source: ESG Times